| Prev Close | 50.13 |
| Open | 49.80 |
| Day Low/High | 47.00 / 49.80 |
| 52 Wk Low/High | 24.87 / 129.71 |
| Volume | 292.37K |
Arcturus Therapeutics Holdings, Inc. (ARCT)
47.91
2.20
4.40
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 26.33B |
| Market Cap | 1.34B |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Here's Why I'm Avoiding AstraZeneca Stock
The AZN affair exposes the seedy underbelly of drug manufacturing, and the COVID-19 vaccine is certainly a drug.
Vaccinate Your Portfolio From the Hype
Let's look at the cold, hard facts around the vaccine rollout.
The Investment Angle of Covid-19
Stocks of companies that have Covid-19 vaccine candidates have boomed while those in the treatment space have not.
Stock-Specific Ideas for the Post-Fed Era of Investing
Make sure that your portfolio is composed of sane assets for the balance of this crazy year.
Where Health Meets Tech: 7 Testing and Diagnostics Stocks to Know
Experts pick their favorite long-term investments in medical diagnostics, testing and laboratory services.
Arcturus Therapeutics Has a Candidate for a Covid-19 Vaccine
When I first started buying ARCT shares I didn't conceive of a valuation of $1 billion, but I also didn't conceive of the global impact of a pandemic.
Mr. Market Has Been Dead Right on General Electric
GE's problem can be summarized in one sentence: The company is burning cash.
Luxor Capital Loves REITs
The hedge fund is buying up shares of American Realty Capital Trust.
